Fiche récapitulative
The project concerns the design, construction and equipment of the company’s new R&D and production facility and includes R&D activities related to the optimisation of purification processes for anti-viral (notably influenza, SARS) and DNA-based biopharmaceuticals by means of the company’s CIM-Technology, as well as to new, or improved anti-viral and biological detection and analysis methods.
The EIB loan under the RSFF scheme would provide co-financing of BIA Separations’ new R&D and production facilities as well as R&D activities.
The construction falls under Annex II of the Directive EU/97/11 amended by Directive 2003/35/EC on Environmental Impact Assessment. The competent authorities’ decision and argumentation for requesting an EIA will be verified during project appraisal.
The promoter is a private company, not operating in the Utilities sector and is thus not covered by EU Directives on procurement. The Bank services will however ascertain that procurement has been carried out in the best interest of the project.